<DOC>
	<DOCNO>NCT01002703</DOCNO>
	<brief_summary>Define maximum tolerable dose combination lenalidomide , bendamustine , prednisone .</brief_summary>
	<brief_title>Treatment With Lenalidomide , Bendamustine Prednisone ( RBP ) Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>1 . Understand voluntarily sign informed consent form . 2 . Age 18 year time signing informed consent form . 3 . Life expectancy least 3 month 4 . Able adhere study visit schedule protocol requirement 5 . Relapsed refractory MM ( first second relapse ) stage II III autologous SCT conventional chemotherapy ( histologically cytologically proven/ Salmon Durie criterion ) detectable myeloma protein blood urine 6 . All previous cancer therapy , include radiation , cytostatic therapy surgery , must discontinue least 4 week prior treatment study , without corticosteroid therapy . 7 . ECOG performance status £ 2 study entry ( see Appendix 01 ) . 8 . Laboratory test result within range 9 . Females childbearing potential must agree contraception abstinence 10 . Disease free prior malignancy ³ 5 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` insitu '' cervix breast 1 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . 2 . Pregnant breast feeding female . 3 . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . 4 . Patients contraindication ( exclusion criterion ) treatment lenalidomide , bendamustine prednisone . 5 . Uncontrolled severe cardiovascular disease , include myocardial infarction within 6 month study entry , New York Heart Association Class III IV heart failure , uncontrolled angina severe uncontrolled ventricular arrhythmia ( ≥ Lown 3 ) . 6 . Use experimental drug therapy within 28 day baseline . 7 . Known hypersensitivity thalidomide purine analogues 8 . The development erythema nodosum characterize desquamate rash take thalidomide similar drug . 9 . Any prior use lenalidomide bendamustine last six month 10 . Concurrent use anticancer agent treatment state treatment plan . 11 . Known positive HIV infectious hepatitis , type A , B C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Lenalidomide</keyword>
	<keyword>Bendamustine</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Myeloma</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Phase I/II</keyword>
	<keyword>refractory Myeloma</keyword>
	<keyword>relapse Myeloma</keyword>
</DOC>